Aidoc lands $150M Series E

Clinical AI is having a platform moment. Hospitals do not just want one algorithm that flags a stroke scan anymore — they want software that plugs into workflows, covers multiple specialties, and actually gets used. That is the backdrop for Aidoc’s new funding round. On April 29, the company said it raised $150 million in Series E financing led by Growth Equity at Goldman Sachs Alternatives, with General Catalyst, SoftBank Vision Fund 2, and NVentures also participating. (am.gs.com) ### What does Aidoc actually sell? Aidoc started in radiology, where its software helps clinicians spot urgent findings in medical images and move the right cases up the queue faster. But the company has been expanding well beyond a single imaging niche — into cardiology, neurovascular care, and broader clinical coordinatio(am.gs.com)ed cases, not just prettier image analysis. (aidoc.com) ### Why is this round a big deal? The headline number matters, but the speed matters too. This $150 million round brings Aidoc’s total funding to over $500 million, and it comes less than a year after another major growth round. That tells you investors are not treating this like a cautious b(aidoc.com). (am.gs.com) ### Where is the company already deployed? Aidoc says its software analyzes more than 60 million patient cases a year and is used across nearly 2,000 hospitals worldwide. Those numbers matter because hospital software is hard to roll out. Selling into one department is one thing. Getting embedded across hundreds or thousand(am.gs.com) (aidoc.com) ### Why do FDA clearances matter here? Healthcare AI does not scale like a consumer chatbot. It has to survive regulation, clinical validation, procurement reviews, and integration with old hospital systems. Aidoc says it now has 31 FDA clearances, and industry coverage frames that as the lar(aidoc.com)get products through the gate. (msn.com) ### What is the money for? Aidoc says the funding will go into its CARE clinical foundation model and its aiOS enterprise platform. In plain English, that means building a bigger shared AI layer underneath multiple clinical products, while also improving the software hospitals use to deploy and manage them. The company also point(msn.com)eakdowns that hurt patients. (aidoc.com) ### Why are investors leaning in now? Because the market is shifting from point solutions to consolidated platforms. Hospitals are tired of buying isolated tools that each solve one narrow problem and create one more integration headache. Investors seem to think Aidoc has crossed into a more (aidoc.com) also why names like Goldman Sachs and NVIDIA’s venture arm stand out here. (am.gs.com) ### Is this still just a radiology story? Not really. Radiology is still the wedge, because imaging gives AI a clear starting point and measurable use cases. But the company’s pitch is getting broader: clinical AI that helps health systems coordinate diagnosis across departments, not just read scans faster. Turns out that is a much bigger business if it works — and a much stickier one. (aidoc.com) ### Bottom line? Aidoc did not just raise money to sell more scan-reading software. It raised platform money. The real bet is that healthcare AI is moving from standalone tools to regulated, hospital-wide systems — and that Aidoc can be one of the companies that owns that layer. (am.gs.com)